Neoadjuvant vs. Adjuvant treatment of Siewert type II gastroesophageal junction cancer: An analysis of data from the surveillance, epidemiology, and end results (SEER) registry

Journal of Gastrointestinal Oncology

Volumn 7, Issue 3, 2016, Pages 403-410

  Miccio, Joseph A ^a   Oladeru, Oluwadamilola T ^a   Yang, Jie ^a,b   Xue, Yaqi ^b   Choi, Minsig ^a   Zhang, Yue ^a   Yoon, Hannah ^a   Ryu, Samuel ^a   Stessin, Alexander M ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Stony Brook University   (United States)

Author keywords

Adjuvant radiation therapy (RT); Gastroesophageal junction (GEJ); Neoadjuvant radiation therapy (neoadjuvant RT); Outcomes research

Indexed keywords

ADJUVANT RADIOTHERAPY; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOADJUVANT RADIOTHERAPY; OVERALL SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SIEWERT TYPE II GASTROESOPHAGEAL JUNCTION CANCER; TREATMENT OUTCOME;

EID: 84995802399     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.21037/jgo.2015.10.06     Document Type: Article

References (24)

1. Blom RL, Bogush T, Brücher BL, et al. Therapeutic approaches to gastroesophageal junction adenocarcinomas. Ann N Y Acad Sci 2014;1325:197-210.
2. Rüdiger Siewert J, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1, 002 consecutive patients. Ann Surg 2000;232:353-61.
3. Siewert JR, Hölscher AH, Becker K, et al. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg 1987;58:25-32.
4. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.
5. Carr RM, Lynch JP. At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?. Gastrointest Cancer Res 2008;2:253-5.
6. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer 2008;123:1422-8.
7. Sehdev A, Catenacci DV. Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov Med 2013;16:103-11.
8. Moehler M, Lyros O, Gockel I, et al. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008;14:3773-80.
9. Krapcho M. SEER Cancer Statistics Review, 1975-2003. 2006.
10. von Rahden BH, Stein HJ, Siewert JR. Surgical management of esophagogastric junction tumors. World J Gastroenterol 2006;12:6608-13.
11. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
12. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
13. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005;90:139-46; discussion 146.
14. Sandler S. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions. Oncology (Williston Park) 2014;28:505-12.
15. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6.
16. Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?. Gastric Cancer 2015;18:1-10.
17. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.
18. Malthaner R. Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy (Cisplatin, 5-FU and Radiotherapy Followed by Surgery) to Surgery Followed by Postoperative Chemoradiation (Cisplatin, Epirubicin, 5-FU, Radiotherapy) for Esophageal Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT00907543
19. Prospective Randomized Phase II Trial Comparing Preoperative Chemoradiotherapy (Paclitaxel and Carboplatin) Followed by Surgery to Surgery Followed by Postoperative Chemoradiotherapy (Paclitaxel and Carboplatin) for Esophageal Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT01463501
20. Meier I, Merkel S, Papadopoulos T, et al. Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition. Int J Radiat Oncol Biol Phys 2008;70:1408-17.
21. Vallböhmer D, Hölscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/emotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 2010;252:744-9.
22. Lee PC, Port JL, Paul S, et al. Predictors of longterm survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann Thorac Surg 2009;88:186-92; discussion 192-3.
23. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005;(4):CD001799.
24. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92.